Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study ; volume:13 ; number:7 ; day:15 ; month:6 ; year:2023 ; pages:1517-1534 ; date:7.2023
Dermatology and therapy ; 13, Heft 7 (15.6.2023), 1517-1534, 7.2023
- Creator
-
Paller, Amy S.
Flohr, Carsten
Eichenfield, Lawrence F.
Irvine, Alan D.
Weisman, Jamie
Soung, Jennifer
Pinto Correia, Ana
Natalie, Chitra R.
Rodriguez Capriles, Claudia
Pierce, Evangeline
Reifeis, Sarah
Gontijo Lima, Renata
Armengol Tubau, Clara
Laquer, Vivian
Weidinger, Stephan
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s13555-023-00942-y
- URN
-
urn:nbn:de:101:1-2023092909432533678397
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:56 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Paller, Amy S.
- Flohr, Carsten
- Eichenfield, Lawrence F.
- Irvine, Alan D.
- Weisman, Jamie
- Soung, Jennifer
- Pinto Correia, Ana
- Natalie, Chitra R.
- Rodriguez Capriles, Claudia
- Pierce, Evangeline
- Reifeis, Sarah
- Gontijo Lima, Renata
- Armengol Tubau, Clara
- Laquer, Vivian
- Weidinger, Stephan
- SpringerLink (Online service)
Other Objects (12)
Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
Atopic dermatitis
Atopic dermatitis
Baseline Body Surface Area and Itch Severity Define Response to Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis at Week 16
Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis
Effect of abrocitinib on skin biomarkers in patients with moderate‐to‐severe atopic dermatitis
Attentiveness and mental health in adolescents with moderate-to-severe atopic dermatitis without ADHD
Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)
Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis
Tralokinumab provides clinically meaningful responses at week 16 in adults with moderate-to-severe atopic dermatitis who do not achieve IGA 0/1
Real-Life Effectiveness and Safety of Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Single-Center 16-Week Study
Adipokines in atopic dermatitis: the link between obesity and atopic dermatitis
Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
Atopic dermatitis
Atopic dermatitis
Baseline Body Surface Area and Itch Severity Define Response to Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis at Week 16
Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis
Effect of abrocitinib on skin biomarkers in patients with moderate‐to‐severe atopic dermatitis
Attentiveness and mental health in adolescents with moderate-to-severe atopic dermatitis without ADHD
Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)
Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis
Tralokinumab provides clinically meaningful responses at week 16 in adults with moderate-to-severe atopic dermatitis who do not achieve IGA 0/1
Real-Life Effectiveness and Safety of Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Single-Center 16-Week Study
Adipokines in atopic dermatitis: the link between obesity and atopic dermatitis
Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
Atopic dermatitis
Atopic dermatitis
Baseline Body Surface Area and Itch Severity Define Response to Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis at Week 16
Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis
Effect of abrocitinib on skin biomarkers in patients with moderate‐to‐severe atopic dermatitis
Attentiveness and mental health in adolescents with moderate-to-severe atopic dermatitis without ADHD
Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)
Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis
Tralokinumab provides clinically meaningful responses at week 16 in adults with moderate-to-severe atopic dermatitis who do not achieve IGA 0/1
Real-Life Effectiveness and Safety of Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Single-Center 16-Week Study